GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reissued by analysts at Berenberg Bank in a research note issued to investors on Wednesday, July 26th. They currently have a GBX 1,885 ($24.86) price target on the stock. Berenberg Bank’s price objective points to a potential upside of 22.88% from the stock’s previous close.
Other equities analysts have also issued reports about the company. Barclays PLC reaffirmed an “equal weight” rating and set a GBX 1,550 ($20.45) price target on shares of GlaxoSmithKline plc in a research note on Monday, July 3rd. Morgan Stanley set a GBX 1,700 ($22.42) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Tuesday, May 2nd. HSBC Holdings plc reaffirmed a “buy” rating and set a GBX 1,970 ($25.99) price target on shares of GlaxoSmithKline plc in a research note on Thursday, April 27th. J P Morgan Chase & Co reaffirmed a “neutral” rating and set a GBX 1,670 ($22.03) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, May 2nd. Finally, BNP Paribas reaffirmed an “underperform” rating and set a GBX 1,520 ($20.05) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, March 28th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of GBX 1,731.62 ($22.84).
Shares of GlaxoSmithKline plc (LON GSK) traded up 0.39% during trading on Wednesday, reaching GBX 1534.00. The company had a trading volume of 4,049,658 shares. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The stock’s 50-day moving average price is GBX 1,625.68 and its 200-day moving average price is GBX 1,626.10. The stock’s market capitalization is GBX 74.98 billion.
COPYRIGHT VIOLATION NOTICE: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/08/05/glaxosmithkline-plcs-longsk-buy-rating-reaffirmed-at-berenberg-bank-updated.html.
In other news, insider Patrick Vallance acquired 861 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was acquired at an average cost of GBX 1,618 ($21.34) per share, for a total transaction of £13,930.98 ($18,376.18). Also, insider Manvinder Singh Banga acquired 2,267 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were purchased at an average price of GBX 1,599 ($21.09) per share, with a total value of £36,249.33 ($47,816.03). Over the last quarter, insiders have purchased 3,150 shares of company stock valued at $5,054,075.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.
